Highlights from the hearings of the new EU Commissioners
by Giuliana Miglierini The hearings of the Commissioners-designate before the relevant committees of the European Parliament closed with…
The first revision of the ERA guideline on environmental risk assessment
by Giuliana Miglierini It took eight years before revision 1 of the EMA guideline on environmental risk assessment…
Mario Draghi’s report, a focus on the proposed actions for the pharma sector
by Giuliana Miglierini The report on the Future of European competitiveness was presented by Mario Draghi on 17…
Reform of pharma legislation: the debate on regulatory data protection
by Giuliana Miglierini As the definition of the final contents of many new pieces of the overall revision…
Lessons learnt to transition from Horizon 2020 to the new FP10
by Giuliana Miglierini The European Commission published the ex post evaluation of Horizon 2020 (H2020), the FP8 framework…
The risk of a biosimilar void in Europe
by Giuliana Miglierini The undergoing revision of the pharmaceutical legislation aims, among others, to redefine data protection to…